Want to see HK:2137 full AI Analyst Report?
Top Page
Brii Biosciences Limited
(2137)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$0.83
▼(-42.08% Downside)
Action:Reiterated
Date:10/04/26
Overall score is weighed down primarily by weak financial performance (ongoing losses and cash burn, plus a sharp 2025 revenue contraction) and bearish technicals (price below key moving averages and negative MACD). A low-debt balance sheet provides some resilience, but negative earnings (negative P/E) and the lack of dividend support keep the score near the lower end of the range.
Positive Factors
Low leverage and positive equity cushion
Very low leverage reduces financial risk and preserves flexibility compared with a highly indebted biotechnology model. Positive equity through 2025 provides a capital cushion that can support ongoing development and commercialization activities, although losses continue to consume resources.
Negative Factors
Persistent losses and deeply negative margins
Persistent losses and deeply negative margins show that the current business has not yet reached sustainable profitability. This weak earnings base can constrain reinvestment, reduce resilience during development setbacks, and leave future financial performance dependent on successful product execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and positive equity cushion
Very low leverage reduces financial risk and preserves flexibility compared with a highly indebted biotechnology model. Positive equity through 2025 provides a capital cushion that can support ongoing development and commercialization activities, although losses continue to consume resources.
Read all positive factors
Brii Biosciences Limited (2137) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$621.37M
Dividend YieldN/A
Average Volume (3M)625.10K
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue GrowthN/A
EPS Growth51.71%
CountryHK
Employees80
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding735,243,600
10 Day Avg. Volume310,600
30 Day Avg. Volume625,096
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.38
Price to Sales (P/S)50.44
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.43
Revenue Forecast (FY)N/A
Brii Biosciences Limited Business Overview & Revenue Model
Company Description
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: earl...
How the Company Makes Money
Brii Biosciences makes money primarily through (1) commercialization revenue from products it markets/sells (where applicable), and (2) collaboration- and licensing-related income tied to partnered assets. Commercialization revenue generally comes...
Brii Biosciences Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.29M | 18.12M | 54.29M | 56.32M | 51.63M | 92.54M |
| Gross Profit | 11.54M | 0.00 | 54.29M | 56.32M | 51.63M | 92.54M |
| EBITDA | -262.17M | -290.29M | -392.51M | -168.20M | -503.58M | -602.80M |
| Net Income | -167.97M | -216.86M | -508.16M | -174.83M | -484.31M | -4.12B |
Balance Sheet | ||||||
| Total Assets | 2.20B | 2.36B | 2.71B | 3.20B | 3.39B | 3.61B |
| Cash, Cash Equivalents and Short-Term Investments | 1.77B | 1.94B | 2.33B | 2.66B | 3.00B | 3.35B |
| Total Debt | 6.18M | 8.93M | 28.02M | 3.16M | 12.66M | 21.62M |
| Total Liabilities | 36.36M | 36.22M | 100.55M | 125.87M | 234.35M | 300.44M |
| Stockholders Equity | 2.22B | 2.38B | 2.66B | 3.12B | 3.19B | 3.34B |
Cash Flow | ||||||
| Free Cash Flow | -247.24M | -288.42M | -376.12M | -643.62M | -635.57M | -880.49M |
| Operating Cash Flow | -235.78M | -286.55M | -372.89M | -594.01M | -496.28M | -879.46M |
| Investing Cash Flow | -813.87M | -151.31M | 895.47M | -104.35M | -1.43B | -475.76M |
| Financing Cash Flow | -23.27M | -39.12M | -9.41M | -10.98M | -3.04M | 3.23B |
Brii Biosciences Limited Technical Analysis
Negative
1.44
Price Trends
0.93
Negative
1.00
Negative
1.24
Negative
Market Momentum
-0.02
Negative
36.65
Neutral
44.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2137, the sentiment is Negative. The current price of 1.44 is above the 20-day moving average (MA) of 0.89, above the 50-day MA of 0.93, and above the 200-day MA of 1.24, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 36.65 is Neutral, neither overbought nor oversold. The STOCH value of 44.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2137.
Brii Biosciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$29.97B | 67.72 | 15.94% | ― | 48.04% | 166.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$2.02B | 20.40 | 48.25% | ― | 88.38% | ― | |
50 Neutral | HK$2.32B | 2.31 | -64.89% | ― | -99.15% | ― | |
44 Neutral | HK$621.37M | -3.07 | -7.32% | ― | ― | 51.71% | |
44 Neutral | HK$2.06B | -2.68 | -24.66% | ― | -18.45% | -151.15% | |
42 Neutral | HK$400.83M | -2.03 | -27.54% | ― | 215.14% | 40.49% |
* Healthcare Sector Average
HK:2137
Brii Biosciences Limited
0.86
-1.45
-62.77%
HK:2181
Mabpharm Limited
0.49
-0.14
-22.22%
HK:2197
Clover Biopharmaceuticals Ltd.
1.79
-1.11
-38.24%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
67.45
39.93
145.09%
HK:6628
Transcenta Holding Limited
0.90
-3.64
-80.18%
HK:6660
AIM Vaccine Co., Ltd. Class H
1.68
-2.77
-62.25%
Brii Biosciences Limited Corporate Events
Brii Biosciences Narrows Interim Loss as HBV and RNA Pipelines Advance
Aug 20, 2026
Brii Biosciences Limited reported unaudited interim results for the six months ended June 30, 2026, showing cash and bank deposits of RMB1.77 billion, down 8.8% mainly due to research and development spending and operating costs. The company narro...
Brii Biosciences Sets August Board Meeting to Approve 2026 Interim Results
Aug 7, 2026
Brii Biosciences Limited has announced that its board of directors will convene on August 20, 2026, to review and approve the unaudited interim results for the six months ended June 30, 2026. The meeting will also address the publication of these ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.